ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2008 Chicago Multidisciplinary Symposium in Thoracic Oncology

Click here to go to the previous page

General Session IV: Mesothelioma

Track : General Session

Program Code: 060

Date: Thursday, November 13, 2008

Time: 1:15 PM to 2:15 PM EST

Duration: 1670 Minutes

Location: Grand Ballroom 1/II

SPEAKER(S):

Click the plus sign to see more detailed information about each speaker.

Michele Carbone, M.D., Ph.D., Director, Thoracic Oncology Program & Professor & Chair, University of Hawaii

Board certified pathologist with a PhD in human pathology. I study how environmental carcinogens (asbestos and erionite mineral fibers), viruses and genetics interact in human carcinogenesis. Mesothelioma is the cancer in which I conduct these studies because my work has demonstrated that genetic predisposition and viral infection can interact with asbestos and erionite to cause this malignancy. Publications: Bocchetta M, Eliasz S, Arakelian De Marco M,Rudzinski J, Zhang L, Carbone M. The SV40 large T Antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res, 68: 1022-1029, 2008 Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA, 103:10397-10402. 2006. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, and Carbone M. Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA, 103: 14128-14133, 2006. Dogan UA, Baris IY, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res, 66:5063-8, 2006. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov K, Minor P, Carbone M. Some oral poliovirus vaccines were contaminated with infectious simian virus 40 after 1961. Cancer Res, 65:10273-79, 2005. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etitology. Cancer Res, 64:5518-5524, 2004. Carbone M, Emri S, Dogan U, Steele I, Tuncer M, Pass HI, Baris YI. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nature Reviews Cancer, 7:147-154, 2007. Malignant Mesothelioma, Advances in Pathogenesis, Diagnosis, and Translational Therapies. Malignant Mesothelioma. Pass, HI, Vogelzang NJ and Carbone M (eds). Springer 2005.

Hedy Kindler, M.D., Medical Oncologist, University of Chicago

Hedy Lee Kindler, MD is an Associate Professor of Medicine at the University of Chicago, where she is the Director of the Mesothelioma and Gastrointestinal Oncology Programs. She also leads the Mesothelioma sub-committee of the Cancer and Leukemia Group B. Dr. Kindler�s research focuses on the investigation of novel agents for the treatment of malignant mesothelioma and pancreatic cancer. Dr. Kindler is an Associate Editor of Lung Cancer. She has been a Guest Editor for Seminars in Oncology and the Hematology/Oncology Clinics of North America. She has published numerous journal articles, review articles, book chapters, and abstracts. Dr. Kindler is the current President of the International Mesothelioma Interest Group. She is also a member of the Science Advisory Board of the Mesothelioma Applied Research Foundation. Dr. Kindler is a member of the American Society of Clinical Oncology, where she has served on a number of committees including the Cancer Research Committee, the Publications Committee, the Biomarkers and Imaging Task Force, the Status of the Oncology Workforce Task Force, and the Quality Clinical Trials Site Working Group. She is the ASCO representative for American Joint Commission on Cancer. Dr. Kindler chaired the Mesothelioma Education Session for the ASCO 2008 Annual Meeting. Dr. Kindler is also an active member of the International Association for the Study of Lung Cancer. She is currently a member of the Core Program Committee for the 13th World Conference on Lung Cancer, and is a member of the Steering Committee for the IASLC-IMIG Mesothelioma Staging Project. Dr. Kindler has been listed repeatedly in Best Doctors in America, America�s Top Physicians, and America�s Top Doctors for Cancer, and was named one of the Top Doctors in Chicago in 2008.

Havey Pass, M.D., Thoracic Surgeon, New York University

Through a series of Phase I, II, and III trials, he explored the use of intraoperative photodynamic therapy (PDT) for the treatment of pleural mesothelioma, as well as the use of adjuvant immunochemotherapy after surgery for mesothelioma. He was one of the first thoracic surgeons to study the use of PDT for thoracic cancers. IHe developed one of the first organized, prospective tissue archives with accurate matching demographics, and used this resource to begin a series of ongoing collaborative studies of the molecular biology of mesothelioma: the discovery of simian virus 40 in human mesothelioma with Dr. Michele Carbone the role of the insulin growth factor receptor in mesothelioma with Dr. Renato Baserga the role of the neurofibromatosis gene in mesothelioma with Dr. John Minna the original findings with Dr. Ira Pastan which led to the discovery of mesothelin. He helped found the Mesothelioma Applied Research Foundation (MARF) in 1998 He published extensively on the angiogenic mechanisms in the disease, as well as further mechanisms of SV40 and asbestos-related carcinogenesis. He conducted novel trials for mesothelioma including the use of a novel antiangiogenesis agent, tetrathiomolybdate, an oral compound which lowers the serum copper for adjuvant therapy after cytoreduction of the disease. His laboratory published novel studies of gene expression array prediction of prognosis in mesothelioma, as well as the discovery of novel molecules in the disease including intelectin. His studies of differences between normal tissues and mesothelioma led to a seminal paper in the New England Journal of Medicine documenting osteopontin as a sensitive and specific serum biomarker for the disease. He was a co-editor of Surgery: Basic Science and Clinical Evidence, and Oncology: An Evidence Based Approach. He also edited Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies and 100 Questions & Answers about Mesothelioma. In 2005, Dr. Pass was recruited to be the first Director of the NYU Division of Thoracic Surgery. His laboratory at Bellevue Hospital is the home of the NCI-funded Early Detection Research Network Biomarker Discovery Laboratory for Mesothelioma, and the Clinical CORE for the NCI�s recently funded Mesothelioma Pathogenesis Program Project. He has solidified NYU�s 3-year Thoracic Fellowship Training Program for individuals interested in general thoracic surgery. The program trains superb surgeons and thoracic scientists for the future. Dr. Pass serves as an Ad Hoc reviewer for publications including New England Journal of Medicine, JAMA, International Journal of Cancer and Journal of Clinical Oncology. He is a vigorous advocate for patients with lung cancer and mesothelioma, serving as a Lung Cancer Alliance Board member, and Chairman of the Scientific Advisory Board for the Mesothelioma Applied Research Foundation. He has been awarded Castle Connolly�s America�s Top Doctors award for the last five years.

Craig Stevens, Radiation Oncologist, H. Lee Moffitt Cancer Ctr. & Research Inst.

Streaming Audio with
PowerPoint Slides

(Code: 060)

Attendee/Member:

Attendee/Member-in-Training:

Attendee/Allied Member:

Attendee/Allied Non-Member:

Attendee/Student:

Attendee/Non-Member:

Member:

Non-Attendee/Member-in-Training:

Non-Attendee/Allied Member:

Non-Attendee/Allied Non-Member:

Residents, Member-in-Training, Students:

Members/Attendees Login